- Home
- PCRX vs BCRX Comparison
PCRX vs BCRX Comparison
Compare PCRX & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- BCRX
- Stock Information
- Founded
- PCRX 2006
- BCRX 1986
- Country
- PCRX United States
- BCRX United States
- Employees
- PCRX N/A
- BCRX N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCRX Health Care
- BCRX Health Care
- Exchange
- PCRX Nasdaq
- BCRX Nasdaq
- Market Cap
- PCRX 1.2B
- BCRX 1.4B
- IPO Year
- PCRX 2011
- BCRX 1994
- Fundamental
- Price
- PCRX $23.96
- BCRX $7.12
- Analyst Decision
- PCRX Strong Buy
- BCRX Strong Buy
- Analyst Count
- PCRX 6
- BCRX 11
- Target Price
- PCRX $33.83
- BCRX $19.00
- AVG Volume (30 Days)
- PCRX 769.6K
- BCRX 4.7M
- Earning Date
- PCRX 11-06-2025
- BCRX 11-03-2025
- Dividend Yield
- PCRX N/A
- BCRX N/A
- EPS Growth
- PCRX N/A
- BCRX N/A
- EPS
- PCRX 0.47
- BCRX N/A
- Revenue
- PCRX $716,791,000.00
- BCRX $599,816,000.00
- Revenue This Year
- PCRX $7.27
- BCRX $41.57
- Revenue Next Year
- PCRX $10.18
- BCRX $6.25
- P/E Ratio
- PCRX $50.52
- BCRX N/A
- Revenue Growth
- PCRX 3.14
- BCRX 45.38
- 52 Week Low
- PCRX $16.29
- BCRX $6.00
- 52 Week High
- PCRX $27.64
- BCRX $11.31
- Technical
- Relative Strength Index (RSI)
- PCRX 56.14
- BCRX 51.36
- Support Level
- PCRX $22.29
- BCRX $6.71
- Resistance Level
- PCRX $24.95
- BCRX $7.17
- Average True Range (ATR)
- PCRX 1.23
- BCRX 0.26
- MACD
- PCRX 0.09
- BCRX 0.01
- Stochastic Oscillator
- PCRX 78.19
- BCRX 67.42
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.